bodies, purifying the protein from the solubilized solution, refolding the protein into a homodimer protein and purifying the homodimer protein.

E4

Claim 47 (amended) The pharmaceutical composition according to claim 28, wherein the disease is chondrodysplasia, chondrohypoplasia, chondrogenesis, palatoschisis and osteodysplasia.

cartilage and/or bone chondrohypoplasia, chosteodysplasia.

ed) The method of claim 40 wherein said bone diseases are chondrodysplasia, chondrogenesis, palatoschisis and

REMARKS

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.

The claims in the application are claims 17 to 48, all other claims having been cancelled.

The Examiner has now required restriction between 1) claims 17 to 28 and 41 to 47 drawn to a polypeptide and pharmaceutical compositions comprising the same, 2) claims 29 and 30 to 33 drawn to a plasmid encoding a polypeptide and the process for producing the encoded polypeptide, and 3) claims 39, 40 and 48 drawn to a method of treatment comprising administering a polypeptide. The